Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.

Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V, Chen W, Schneider A, Gutkind JS.

Cancer Prev Res (Phila). 2012 Apr;5(4):562-73. doi: 10.1158/1940-6207.CAPR-11-0502. Epub 2012 Mar 31.

2.

Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.

Patel H, Younis RH, Ord RA, Basile JR, Schneider A.

J Oral Pathol Med. 2013 Mar;42(3):250-6. doi: 10.1111/j.1600-0714.2012.01196.x. Epub 2012 Aug 3.

PMID:
22861817
3.

Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN Jr, Seethala RR, Ferris RL, Gutkind JS.

Cancer Prev Res (Phila). 2015 Mar;8(3):197-207. doi: 10.1158/1940-6207.CAPR-14-0348. Epub 2015 Feb 13.

4.

Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.

Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS.

Cancer Prev Res (Phila). 2009 Jan;2(1):27-36. doi: 10.1158/1940-6207.CAPR-08-0147.

5.

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.

Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G.

Cell Metab. 2010 May 5;11(5):390-401. doi: 10.1016/j.cmet.2010.03.014.

6.

Metformin prevents tobacco carcinogen--induced lung tumorigenesis.

Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA.

Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76. doi: 10.1158/1940-6207.CAPR-10-0055. Epub 2010 Sep 1.

7.

Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.

De Costa AM, Justis DN, Schuyler CA, Young MR.

Int Immunopharmacol. 2012 Jul;13(3):322-30. doi: 10.1016/j.intimp.2012.05.004. Epub 2012 May 16.

8.

Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.

Liu CJ, Chang WJ, Chen CY, Sun FJ, Cheng HW, Chen TY, Lin SC, Li WC.

Oncotarget. 2015 Oct 6;6(30):29268-84. doi: 10.18632/oncotarget.4922.

9.

Metformin inhibits skin tumor promotion in overweight and obese mice.

Checkley LA, Rho O, Angel JM, Cho J, Blando J, Beltran L, Hursting SD, DiGiovanni J.

Cancer Prev Res (Phila). 2014 Jan;7(1):54-64. doi: 10.1158/1940-6207.CAPR-13-0110. Epub 2013 Nov 6.

10.

ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis.

Hasina R, Martin LE, Kasza K, Jones CL, Jalil A, Lingen MW.

Cancer Prev Res (Phila). 2009 Apr;2(4):385-93. doi: 10.1158/1940-6207.CAPR-08-0211. Epub 2009 Mar 31.

11.

Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.

Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC.

Am J Respir Cell Mol Biol. 2013 Aug;49(2):241-50. doi: 10.1165/rcmb.2012-0244OC.

PMID:
23526220
12.

Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.

Bothwell KD, Shaurova T, Merzianu M, Suresh A, Kuriakose MA, Johnson CS, Hershberger PA, Seshadri M.

Cancer Prev Res (Phila). 2015 Sep;8(9):765-76. doi: 10.1158/1940-6207.CAPR-14-0454. Epub 2015 Jun 22.

13.

Hyperactive mTORC1 signaling is unaffected by metformin treatment in aged skeletal muscle.

Dungan CM, Li Z, Wright DC, Williamson DL.

Muscle Nerve. 2016 Jan;53(1):107-17. doi: 10.1002/mus.24698. Epub 2015 Nov 23.

PMID:
25926238
14.

Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.

Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB.

Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4.

15.

Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.

Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR.

Cancer Prev Res (Phila). 2011 Feb;4(2):230-7. doi: 10.1158/1940-6207.CAPR-10-0249. Epub 2010 Dec 16.

17.

Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.

Young MR, Levingston CA, Johnson SD.

Int J Cancer. 2016 May 15;138(10):2487-98. doi: 10.1002/ijc.29989. Epub 2016 Jan 28.

18.

The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.

Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, Wang X, He D, Jin X.

Int J Mol Sci. 2013 Dec 18;14(12):24603-18. doi: 10.3390/ijms141224603.

19.

Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids.

Li H, Lee J, He C, Zou MH, Xie Z.

Am J Physiol Endocrinol Metab. 2014 Jan 15;306(2):E197-209. doi: 10.1152/ajpendo.00202.2013. Epub 2013 Dec 3.

20.

Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.

Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L, Athar M.

Photochem Photobiol. 2012 Sep-Oct;88(5):1149-56. doi: 10.1111/j.1751-1097.2012.01165.x. Epub 2012 Jun 1.

Supplemental Content

Support Center